HealthcareServices

Global Cancer Tumor Profiling Market Analysis 2025–2029: Opportunities for Strategic Growth

November 24, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Cancer Tumor Profiling Market Expected To Become By 2029 Compared With Its 2025 Level?

The cancer tumor profiling market size has seen rapid growth in recent years. It is expected to expand from $13 billion in 2024 to $14.97 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.1%. This historic period’s growth can be attributed to factors such as increasing cancer incidence, the expansion of precision medicine initiatives and research collaborations, enhancements in cancer diagnostics and early detection methods, the availability of diverse targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $25.12 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 13.8%. Key drivers for this growth during the forecast period include the broader application of immunotherapy and immunoprofiling in cancer therapies, the advancement of liquid biopsy and non-invasive tumor profiling techniques, the utilization of single-cell sequencing for in-depth tumor analysis, the spread of cancer screening and early detection initiatives, and a rising need for profiling rare and orphan cancer subtypes. Significant trends expected in the same period encompass the incorporation of tumor profiling into standard clinical procedures, breakthroughs in multi-omics methodologies, the integration of artificial intelligence (AI) and machine learning for data interpretation, the evolution of personalized medicine and targeted therapies, and ongoing progress in genomics and next-generation sequencing (NGS) technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

Which Drivers Are Supporting Growth Of The Cancer Tumor Profiling Market?

The global rise in cancer occurrences is projected to stimulate the future expansion of the cancer and tumor profiling market. Cancer is defined as a condition where certain body cells multiply without restraint and spread to different parts of the body. With an increasing number of cancer diagnoses, the need for cancer tumor profiling also escalates, as it assists medical professionals in assessing the disease’s severity. For example, in 2024, the American Cancer Society, a professional organization based in the US, reported 2 million new cancer cases diagnosed in the country, an increase from 1.9 million new cases in 2023. Therefore, the growing worldwide prevalence of cancer is driving the growth of the cancer and tumor profiling market.

What Are The Segment Types Shaping The Cancer Tumor Profiling Market?

The cancer tumor profilingmarket covered in this report is segmented –

1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types

2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies

3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types

4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications

Subsegments:

1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)

2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer

3) By Colorectal Cancer: Colon Cancer; Rectal Cancer

4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer

5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma

6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer

7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)

8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors

9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer

10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer

What Long-Term Trends Will Shape The Future Growth Of The Cancer Tumor Profiling Industry?

Increasing research and development activities have emerged as a prominent trend gaining traction in the cancer and tumor profiling market. Major companies operating within the cancer and tumor profiling sector are prioritizing research and development efforts to address consumer demand and solidify their market position. For instance, QIAGEN N.V., a German company specializing in sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research, announced the Conformitè Europëenne (CE)-marking and commercialization of its therascreen PIK3CA RGQ PCR Kit in Europe. This kit is intended as a tool to assist in identifying breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test functions as a diagnostic assay for detecting an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and it is the first to enable testing of DNA from both plasma specimens or FFPE tissue.

Which Leading Players Are Enhancing Their Cancer Tumor Profiling Market Presence Worldwide?

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Cancer Tumor Profiling Market?

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Cancer Tumor Profiling Market Report:

https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2025, By The Business Research Company

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Tumor Ablation Therapy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795